Report Description and Highlights

Drug-Resistant Epilepsy Market Trend:

The elevating cases of brain structural abnormalities, like vascular malformations and tumors, resulting from previous brain injuries or surgeries, which can alter the electrical network and interfere with the effectiveness of anti-seizure medications, are primarily augmenting the drug-resistant epilepsy market. Additionally, the increasing incidences of inherited defects that cause genetic variations in drugmetabolizing enzymes, drug transporters, or target receptors are further stimulating the market growth. Besides this, the escalating application of effective therapeutic agents, including vigabatrin, cannabidiol, felbamate, etc., to manage the symptoms of drug-resistant epilepsy is acting as another significant growth-inducing factor.

Furthermore, the growing demand for neurofeedback therapy, a non-invasive technique to potentially encourage self-regulation and increase independence in the daily activities of patients, is also contributing to the market growth. Apart from this, the rising adoption of neuromodulation devices, including vagus nerve stimulation, responsive neurostimulation, deep brain stimulation, etc., to disrupt abnormal brain patterns and reduce seizures is projected to fuel the drug-resistant epilepsy market over the forecasted period.

Request a Sample Report: https://www.imarcgroup.com/drug-resistant-epilepsy-market/requestsample